RLAY vs SDGR
RLAY and SDGR side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | SDGRSchrodinger, Inc. |
|---|---|---|
| Market cap | $4.20B | — |
| P/S | 273.7x | — |
| Revenue | — | $259.04M(TTM) |
| Revenue growth (YoY) | 53.4% | 23.3% |
| Net income | — | -$54.34M(TTM) |
| Earnings growth (YoY) | 18.1% | 44.8% |
| EPS, diluted | — | $-0.73(TTM) |
| EBIT margin | -1971.6% | -65.2% |
| ROE | -31.1% | -31.4% |
| 1y total return | +380.0% | +7.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RLAY vs SDGR
| Metric | RLAY | SDGR |
|---|---|---|
| End value | $5.5K | $2.6K |
| Total return | -45.3% | -74.3% |
| CAGR | -9.3% | -19.8% |
| Volatility | 76.8% | 64.2% |
| Sharpe | 0.20 | -0.09 |
| Sortino | 0.30 | -0.13 |
| Max drawdown | -96.8% | -90.2% |
Based on 1548 common trading days, 2020-07-16 → 2026-09-14 · risk-free 4.07% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)